At the estimate market size of $422 million for 12 months, the generic version of Prilosec delayed-release capsules by Aurobindo Pharma will be launched in the US
Aurobindo Pharma has received the green signal from the USFDA to market the generic version of Prilosec delayed-release capsule in the strengths of 10mg, 20mg, and 40 mg in the American market. The company has got the permission to manufacture and market Omeprazole delayed-release, used for short-term treatment of active duodenal ulcer in adults.
As confirmed by PTI,
The company’s approved abbreviated new drug application (ANDA) is a generic version of AstraZeneca Pharmaceuticals’ Prilosec capsules, confirmed the company in a media statement,
According to IMS, the product had an estimated market size of USD 422 million for the twelve months ended June 30.
In a separate statement, the company said it has received approval from the USFDA to market generic version of Hoffmann-La Roche’s Boniva injection in the American market.
The company’s Ibandronate Sodium injection is indicated for the treatment of osteoporosis in postmenopausal women.